Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors
Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors
Recruiting · NCT05868174 · Registry updated 2024-05-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | Advanced Renal Cell Carcinoma; Advanced Solid Tumor; Solid Tumor, Adult | Recruiting | Phase 1 | 2024-05-01 | NCT05868174 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck KGaA, Darmstadt, Germany | 31 |
| Telix Pharmaceuticals (Innovations) Pty Limited | 11 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ashford (Icon) Cancer Centre | Adelaide | Australia | 1 |
| Austin Health | Melbourne | Australia | 5 |
| GenesisCare Murdoch | Perth | Australia | 1 |
| Macquarie University | North Ryde | Australia | 2 |
| Princess Alexandra Hospital | Brisbane | Australia | 11 |